دورية أكاديمية

Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018.

التفاصيل البيبلوغرافية
العنوان: Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018.
المؤلفون: Lestrade, Pieter P. A., Buil, Jochem B., van der Beek, Martha T., Kuijper, Ed J., van Dijk, Karin, Kampinga, Greetje A., Rijnders, Bart J. A., Vonk, Alieke G., de Greeff, Sabine C., Schoffelen, Annelot F., van Dissel, Jaap, Meis, Jacques F., Melchers, Willem J. G., Verweij, Paul E.
المصدر: Emerging Infectious Diseases; Jul2020, Vol. 26 Issue 7, p1447-1455, 9p, 2 Charts, 4 Graphs
مصطلحات موضوعية: ANTIFUNGAL agents, PROTEINS, RESEARCH, HETEROCYCLIC compounds, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, DRUG resistance in microorganisms, ASPERGILLUS, MICROBIAL sensitivity tests, PHARMACODYNAMICS
مصطلحات جغرافية: NETHERLANDS
مستخلص: We investigated the prevalence of azole resistance of Aspergillus fumigatus isolates in the Netherlands by screening clinical A. fumigatus isolates for azole resistance during 2013-2018. We analyzed azole-resistant isolates phenotypically by in vitro susceptibility testing and for the presence of resistance mutations in the Cyp51A gene. Over the 6-year period, 508 (11%) of 4,496 culture-positive patients harbored an azole-resistant isolate. Resistance frequency increased from 7.6% (95% CI 5.9%-9.8%) in 2013 (58/760 patients) to 14.7% (95% CI 12.3%-17.4%) in 2018 (112/764 patients) (p = 0.0001). TR34/L98H (69%) and TR46/Y121F/T289A (17%) accounted for 86% of Cyp51A mutations. However, the mean voriconazole MIC of TR34/L98H isolates decreased from 8 mg/L (2013) to 2 mg/L (2018), and the voriconazole-resistance frequency was 34% lower in 2018 than in 2013 (p = 0.0001). Our survey showed changing azole phenotypes in TR34/L98H isolates, which hampers the use of current PCR-based resistance tests. [ABSTRACT FROM AUTHOR]
Copyright of Emerging Infectious Diseases is the property of Centers for Disease Control & Prevention (CDC) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10806040
DOI:10.3201/eid2607.200088